Literature DB >> 10945495

Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization.

L Boldrini1, A Calcinai, E Samaritani, F Pistolesi, A Mussi, M Lucchi, C A Angeletti, F Basolo, G Fontanini.   

Abstract

Recent in vivo and in vitro studies have demonstrated a wide spectrum of biologic activities of cytokines in the pathogenesis and progression of malignancy. Tumour necrosis factor alpha (TNF-alpha) and transforming growth factor beta (TGF-beta) have emerged as two of the many host-derived mediators that seem to interfere with both antiproliferative and tumorigenic effects in malignant tumours including lung cancer. However, their association with tumour prognosis or prognostic factors has not yet been completely clarified. In this study, we assessed TNF-alpha and TGF-beta mRNA expression by RT-PCR technique in 61 NSCLC samples, demonstrating the presence of TNF-alpha and TGF-beta mRNA in 55.74% and 45.9% of cases, respectively. We also evaluated the expression of the two distinct transmembrane TNF receptors. TNFR-I and TNFR-II, with a PCR-positive signal in 70.49% and 65.57% of cases, respectively. In 49 of the 61 cases, we evaluated the prognostic impact of the two growth-inhibiting factors using the Kaplan-Meier analysis. In the univariate analysis patients without nodal metastatic involvement (P = 0.02), less advanced tumour stage (P = 0.02) or TNF-alpha and TGF-beta positive cancers (P = 0.01 and P = 0.03) showed a favourable prognosis in terms of overall survival. Since our previous studies demonstrated a significant association between NSCLC behaviour, neoangiogenesis and bcl-2 expression, we investigated the putative relation between TNF-alpha and TGF-beta on the one hand, and vascular count (as a measure of tumour angiogenesis) and bcl-2 protein expression, on the other hand. Our results showed a significant direct association between TNF-alpha and bcl-2 (P = 0.05) and an inverse association between TNF-alpha and microvessel count (P = 0.03). Moreover, as previously demonstrated, we observed a significant inverse correlation between bcl-2 protein expression and vascular count (P = 0.05), suggesting that the favourable effect of TNF-alpha on clinical outcome may be related to a bcl-2-mediated low neovascular development.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10945495      PMCID: PMC2374649          DOI: 10.1054/bjoc.2000.1345

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  36 in total

Review 1.  Tumor interactions with the vasculature: angiogenesis and tumor metastasis.

Authors:  C H Blood; B R Zetter
Journal:  Biochim Biophys Acta       Date:  1990-06-01

2.  Anti-proliferative effects of tumor necrosis factor, gamma interferon and 5-fluorouracil on human colorectal carcinoma cell lines.

Authors:  J H Schiller; G Bittner
Journal:  Int J Cancer       Date:  1990-07-15       Impact factor: 7.396

3.  Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).

Authors:  J L Cordell; B Falini; W N Erber; A K Ghosh; Z Abdulaziz; S MacDonald; K A Pulford; H Stein; D Y Mason
Journal:  J Histochem Cytochem       Date:  1984-02       Impact factor: 2.479

Review 4.  Growth regulation of human breast carcinoma occurs through regulated growth factor secretion.

Authors:  M E Lippman; R B Dickson; E P Gelmann; N Rosen; C Knabbe; S Bates; D Bronzert; K Huff; A Kasid
Journal:  J Cell Biochem       Date:  1987-09       Impact factor: 4.429

5.  Effect of recombinant monokines, lymphokines, and other agents on clonal proliferation of human lung cancer cell lines.

Authors:  M Munker; R Munker; R E Saxton; H P Koeffler
Journal:  Cancer Res       Date:  1987-08-01       Impact factor: 12.701

6.  A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma.

Authors:  N Kemeny; B Childs; W Larchian; K Rosado; D Kelsen
Journal:  Cancer       Date:  1990-08-15       Impact factor: 6.860

7.  Induction of lymphokine-activated killer cytotoxicity with interleukin-2 and tumor necrosis factor-alpha against primary lung cancer targets.

Authors:  S C Yang; L Owen-Schaub; E A Grimm; J A Roth
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

8.  Transforming growth factor-beta: biological function and chemical structure.

Authors:  M B Sporn; A B Roberts; L M Wakefield; R K Assoian
Journal:  Science       Date:  1986-08-01       Impact factor: 47.728

9.  Colony inhibitory effect of recombinant human tumor necrosis factor (rH-TNF) and/or recombinant human interferon (rH-IFN)-alpha, -beta and -gamma on human lung cancer cell lines.

Authors:  W S Hong; J R Jett; Y Sasaki; H Takahashi; H Nakano; K Nakagawa; A Hoshi; N Saijo
Journal:  Jpn J Clin Oncol       Date:  1987-03       Impact factor: 3.019

10.  Expression of tumour necrosis factor alpha and its receptors in carcinoma of the breast.

Authors:  L Pusztai; L M Clover; K Cooper; P M Starkey; C E Lewis; J O McGee
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

View more
  13 in total

1.  Modulation of peripheral immune responses by paclitaxel-ifosfamide-cisplatin chemotherapy in advanced non-small-cell lung cancer.

Authors:  Nikolaos Koufos; Despina Michailidou; Ioannis D Xynos; Periclis Tomos; Kalliopi Athanasiadou; Christos Kosmas; Nikolaos Tsavaris
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-26       Impact factor: 4.553

Review 2.  Cellular and molecular immunology of lung cancer: therapeutic implications.

Authors:  Austin Huy Nguyen; Ilya G Berim; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2014-10-28       Impact factor: 4.473

3.  Membrane versus soluble isoforms of TNF-α exert opposing effects on tumor growth and survival of tumor-associated myeloid cells.

Authors:  Shidrokh Ardestani; Bin Li; Desirae L Deskins; Huiyun Wu; Pierre P Massion; Pampee P Young
Journal:  Cancer Res       Date:  2013-05-23       Impact factor: 12.701

4.  Tumour necrosis factor-alpha expression in tumour islets confers a survival advantage in non-small cell lung cancer.

Authors:  Chandra M Ohri; Aarti Shikotra; Ruth H Green; David A Waller; Peter Bradding
Journal:  BMC Cancer       Date:  2010-06-23       Impact factor: 4.430

5.  TNFRSF1B +676 T>G polymorphism predicts survival of non-small cell lung cancer patients treated with chemoradiotherapy.

Authors:  Xiaoxiang Guan; Zhongxin Liao; Hongxia Ma; Ji Qian; Zhensheng Liu; Xianglin Yuan; Daniel Gomez; Ritsuko Komaki; Li-E Wang; Qingyi Wei
Journal:  BMC Cancer       Date:  2011-10-14       Impact factor: 4.430

6.  Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC(R) is a predictor for relapse: A preliminary report.

Authors:  Axel Rolle; Rainer Günzel; Ulrich Pachmann; Babette Willen; Klaus Höffken; Katharina Pachmann
Journal:  World J Surg Oncol       Date:  2005-03-31       Impact factor: 2.754

7.  Upregulation of long non-coding RNA PlncRNA-1 promotes proliferation and induces epithelial-mesenchymal transition in prostate cancer.

Authors:  Yang Jin; Zilian Cui; Xudong Li; Xunbo Jin; Jian Peng
Journal:  Oncotarget       Date:  2017-04-18

8.  The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer.

Authors:  S Al-Saad; K Al-Shibli; T Donnem; M Persson; R M Bremnes; L-T Busund
Journal:  Br J Cancer       Date:  2008-10-14       Impact factor: 7.640

9.  Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines.

Authors:  Grégoire Wieërs; Nathalie Demotte; Danièle Godelaine; Pierre Van der Bruggen
Journal:  Cancers (Basel)       Date:  2011-07-18       Impact factor: 6.639

Review 10.  Mechanistic basis and clinical relevance of the role of transforming growth factor-β in cancer.

Authors:  Run-Long Lin; Lu-Jun Zhao
Journal:  Cancer Biol Med       Date:  2015-12       Impact factor: 4.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.